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Abstract: The aim of the development of composite mate-
rials is to combine the most desired properties of two or
more materials. In this work, the biodegradable character,
good controlled-release properties, and natural origin of
starch-based biomaterials are combined with the bioactive
and bone-bonding properties of bioactive glass (BG). Novel,
bioactive composite starch–BG microparticles were synthe-
sized starting from a blend of starch and polylactic acid
(50%/50% wt) with BG 45S5 powder using a simple emul-
sion method. Morphological and chemical characterization
showed that these particles exhibited a spherical morphol-
ogy with sizes up to 350 m and that BG 45S5 was incor-
porated successfully into the composite particles. Upon im-
mersion in a solution simulating body ﬂuids, for periods up
to 3 weeks, their bioactive nature was conﬁrmed, as a calci-
um-phosphate layer resembling biological apatite was
formed onto their surface. The short-term cytotoxicity of
these materials was also tested by placing 24-h leachables of
the materials extracted in culture medium in contact with a
ﬁbroblastic cell line (L929) up to 72 h. At this time period,
two biochemical tests—MTT and total protein quantiﬁca-
tion—were performed. The results showed that these mate-
rials are not cytotoxic. These results constitute the basis of
future encapsulation studies using bone-acting therapeutic
agents such as bone morphogenetic proteins or other bone-
relevant factors. The particles developed here may be very
useful for applications in which controlled release, degrad-
ability, and bone-bonding ability are the main requirements.
© 2004 Wiley Periodicals, Inc. J Biomed Mater Res 70A:
442–449, 2004
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INTRODUCTION
A bioactive bone-bonding material is one that elicits
a speciﬁc biological response at the interface of the
material, which results in the formation of a bond
between the tissues and the material.1,2 To date, no
polymer displayed by itself a bioactive behavior (un-
less pretreatments have been performed). One strat-
egy to promote their bioactivity is to combine poly-
mers and ceramics, thus creating composite materials
that exhibit a range of properties that derive from both
constituent materials. This way, it is possible to create
materials that mitigate the lack of satisfactory proper-
ties of both polymers and ceramics.2 The use of starch-
based materials can be justiﬁed by the well-known
acidiﬁcation phenomenon when using systems consti-
tuted by polylactic acid. Using natural-origin materi-
als, this problem can be readily overcome because
starch can be degraded within the body by several
enzymes,3 resulting in degradation products (carbo-
hydrates) that can be readily metabolized and ex-
creted.
Starch-based polymers are being studied for a wide
range of bone-related therapy applications, ranging
from tissue engineering scaffolds,4 to bone cements5
and drug delivery systems.6 Its natural origin, to-
gether with its mechanical properties7–9 and biocom-
patibility10,11 support the potential of starch-based
materials in the biomedical ﬁeld. As for bioactive glass
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(BG) 45S5 (with a nominal composition of 46.1% SiO2,
24.4% Na2O, 26.9% CaO, 2.6% P2O5 mol %), its rapid
rate of surface reaction leads to fast tissue bonding
when compared with other ceramic materials. Biolog-
ical properties of BG 45S5 have been extensively stud-
ied12–14 and, as shown in vitro, it was found to enhance
extracellular matrix formation and promote the osteo-
blastic phenotypic expression.15
Starch microparticles have already been shown6 to
be excellent for the controlled release of meclofenamic
acid, an anti-inﬂammatory agent, and for the release
of glucocorticoid agents such as dexamethasone.16
When combining these properties with the advanta-
geous bone-bonding properties of BG 45S5, there is a
distinct potential for these particles to be used as
controlled-release systems of either bone-acting drugs
or growth factors. In principle, these systems would
be able to bond to bone and at the same time act as
drug-release systems. In theory, the presence of a
bone-bonding material (BG) would enhance small-de-
fect bone repair whereas, simultaneously, the biode-
gradable material would act as a scaffold for cell
growth, by releasing incorporated growth factors. This
release would stimulate cell proliferation and differ-
entiation, thus achieving a faster repair.
In the present study, we synthesized composite mi-
croparticles composed of a starch-based material and
of BG 45S5. These particles display a bioactive behav-
ior, as seen by the formation of a calcium-phosphate
layer resembling biological apatite at their surface
upon immersion in a solution simulating body ﬂuid.
As for all newly proposed biomaterials, a cytotoxic
screening must be performed as a preliminary step in
the process of the determination of the compatibility
with biological systems (biocompatibility). In this
work, the short-term cytotoxicity of the developed
materials was tested by means of minimum essential
medium (MEM) extraction tests.
MATERIALS AND METHODS
Materials
A commercial blend of starch and polylactic acid (SPLA)
(50%/50% wt) (Novamont, Italy) was used as raw material
for the production of the microparticles. BG 45S5 (46.1%
SiO2, 24.4% Na2O, 26.9% CaO, 2.6% P2O5, mol %) was ob-
tained from MO-SCI (Rolla, MO) and ground before use to a
particle size smaller than 60 m.
For particle synthesis, methylene chloride and polyvinyl
alcohol 87–89% hydrolyzed, were used as received. The
following chemicals were used for preparing the simulated
body solution, herein designated as TE (Tris with electro-
lytes): 0.05M Tris buffer solution, Trizma-HCl, sodium chlo-
ride (NaCl), potassium chloride (KCl), sodium hydrogen
carbonate (NaHCO3), magnesium chloride hexahydrated
(MgCl2  6H2O), magnesium sulphate heptahydrated
(MgSO4  7H2O), dipotassium hydrogen phosphate anhy-
drous (K2HPO4), and calcium chloride anhydrous (CaCl2),
used as received.
Synthesis of SPLA and SPLA/BG particles
SPLA particles were produced by an emulsiﬁcation
method adapted from Qiu et al.17 The method was modiﬁed
as follows: 1 g of SPLA was dissolved in 10 mL of methylene
chloride and this solution was added to 200 mL of a stirring
0.5% polyvinyl alcohol solution and emulsiﬁed for 5 h in a
Caframo dual-range stirrer (Fisher Scientiﬁc, Hampton, NH)
at a speed of 660 rpm/min. The particles were then washed
and separated from the solution by ﬁltration. They were
dried, separated by size, and stored in a desiccator.
The SPLA/BG composite particles were produced follow-
ing the methodology described above, to which 30% of the
starch-based material weight of BG 45S5 was added to the
starch solution.
SPLA and SPLA/BG particles morphological
characterization
The synthesized particles were morphologically charac-
terized by light microscopy and scanning electron micros-
copy (SEM) and size distribution was determined for each
condition by sieving. The particles were observed and pho-
tographed in an optical microscope with an image acquisi-
tion system (high-resolution color video camera and Image-
Pro Plus analysis software; Media Cybernetics, Silver
Spring, MD). SEM analysis was performed on gold-coated
samples.
Size distribution was obtained by determining the weight
of each of the obtained fractions after sieving in a sonic sifter
(ATM sonic sifter, model L3P; ATM Co., Milwaukee, WI).
For the determination of the size distribution, measurements
were made at least in triplicate.
Immersion–bioactivity evaluation
SPLA and SPLA/BG particles of a size range between
210–350 m were used for in vitro testing of their bioactivity
in a 0.05M Tris hydroxymethyl aminomethane-buffered so-
lution complemented with electrolytes typical for plasma
(TE). The use of this solution was described previously.18
SPLA-based particles were immersed in TE at a ratio of 5
and 3 mg/mL, for SPLA and SPLA/BG particles, respec-
tively, in a CO2 incubator at 37°C. The vials were placed on
an orbital shaker at a rotational speed of 150 rpm for up to
21 days without solution exchange. At designated time
points (1, 2, 3, 7, 10, 14, and 21 days), the samples were
removed from the shaker, the pH was measured, and the
particles were separated from the solution by ﬁltration. The
latter were then dried and stored in a desiccator until further
analysis. The post-immersion solutions were used to per-
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form chemical analysis, namely for changes in Ca, Si, and P
concentrations. Ca and Si concentrations were measured by
atomic absorption spectrophotometry. For the Ca measure-
ments, a solution of 1% LaCl3 was used, whereas the Si
measurements were performed directly from the post-im-
mersion solution. For the P measurements, an ultraviolet–
visible spectrophotometer was used at 400 nm and a color-
imetric method was employed.19 Samples were also
analyzed by ICP-OES (inductively coupled plasma–optical
emission spectroscopy).
Further characterization of the immersed particles was
performed using Fourier transform infrared–attenuated re-
ﬂection (FTIR-ATR), SEM/energy dispersive X-ray spectros-
copy (EDS) analysis and X-ray diffraction (XRD) analysis.
Short-term cytotoxicity evaluation
For cytotoxicity evaluation by indirect contact with the
materials, two different tests were performed, namely MTT
and total protein quantiﬁcation test.
The cells used in this study were an immortalized cell line
of subcutaneous areolar ﬁbroblasts from mouse origin pur-
chased from Collection of Cell Culture (ECACC, UK, ref.
85011425), designated L929. The cells were grown in mono-
layer systems in Dulbecco’s modiﬁed eagle medium supple-
mented (as described in the next section) and used between
passages 6 and 12.
MTT
The MTT test is a biochemical test widely used to assess
cytotoxicity by measuring cell viability and proliferation in a
qualitative way.20,21 This biochemical test is based in the
reduction of [3-(4,5-dimethylthiazol-2-yl)-2,4-diphenyltetra-
zolium bromide] (which is water-soluble and has a yellow
tonality) by the cell mitochondrial enzyme succinate dehy-
drogenase, yielding a purple-color salt insoluble in water.22
The salt absorbs at a wavelength of 570 nm and because only
living cells have the capability to metabolize the MTT, it
gives a measurement of the viable cells.22
The procedure followed for this test was as described
previously23 and corresponds to the ISO MEM elution test
for short-term cytotoxicity assessment. Brieﬂy, SPLA and
SPLA/BG particles were placed in conic tubes with Dulbec-
co’s modiﬁed Eagle medium and placed under constant
shaking (60 rpm) at 37°C for 24 h for the materials to release
eventual leachables (formation of extracts from the materi-
als). An extraction control was performed, which consists of
Dulbecco’s modiﬁed Eagle medium, placed in the same
conditions as the samples. This control was performed to
assure that the extraction conditions by themselves do not
alter the properties of the culture medium. After 24 h, the
extracts were ﬁltered through a 0.45-m pore size ﬁlter,
placed in contact with an 80–90% conﬂuence cells’ mono-
layer and further incubated for 72 h. After this time period,
the viability of the cells was evaluated by the MTT test by
measuring the optical density. All the materials were tested
in 10 replicates for each extract for at least two independent
experiments with reproducible results. The results are ex-
pressed as a percentage of the control (scored as 100% via-
bility) as mean  standard errors.
Total protein quantification
The method that was used to quantify the total protein
uses the Micro BCA Protein Assay Reagent Kit, in which
bicinchoninic acid (BCA) is the detection reagent for a Cu
complex, which is formed when Cu2 is reduced by proteins
in an alkaline environment.24 The purple-color product is
due to the chelation of two molecules of BCA with one Cu
ion. This complex is water-soluble and absorbs at 562 nm,
and its optical density is linearly correlated with protein
concentration.24
The procedure followed is as described for the MTT test.
After the 72-h incubation, the cells were washed with phos-
phate-buffered saline and the BCA reagent was added. After
an incubation period, the optical densities were measured.
Total protein (in micrograms) was determined using a bo-
vine serum albumin standard curve.
All the materials were tested in 10 replicates for each
extract for at least three separate experiments, with repro-
ducible results. The results are expressed as percentage of
the control (scored as 100% viability) as mean  standard
errors.
RESULTS AND DISCUSSION
Synthesis of SPLA and SPLA/BG particles
The size distribution for SPLA and SPLA/BG par-
ticles (Fig. 1) clearly shows that the size range of
210–350 m predominates, whereas particles with
sizes 350 m are absent and 40 m are only a
minor fraction. This allows stating that the addition of
BG to form composite particles does not signiﬁcantly
Figure 1. SPLA and SPLA/BG particle size distribution.
After sieving, each size interval was weighted and its rela-
tive amount was determined. The graph shows that both
conditions present similar size-distribution patterns, which
indicates that the addition of BG 45S5 powder does not seem
to affect the size distribution of the particles.
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affect the size distribution of the starch-based parti-
cles.
Morphology of SPLA and SPLA/BG particles
The morphology of polymer and composite parti-
cles was evaluated by optical microscopy (Fig. 2) cou-
pled to an image acquisition system. It was also ana-
lyzed using SEM (Fig. 3).
The morphology of the particles as revealed by light
microscopy was indifferent of the type of particles.
The particles were approximately spherical, which
was further conﬁrmed by SEM analysis. In addition,
this examination also showed that their surfaces were
quite similar, with smooth areas intercalating with
rougher ones, and with some cavities being present. In
Figure 3(C) (a detail of a typical particle surface), some
pores/cavities can be seen. On the composite particles
there are no surface features that might be distinctive
for the presence of BG 45S5.
Bioactivity evaluation: chemical analysis
To evaluate the bioactivity of the synthesized parti-
cles, both sets of samples—SPLA and SPLA/BG par-
ticles—were immersed in a Tris buffer complemented
with electrolytes (TE) for durations up to 21 days.
Figure 4(A–C) displays the results of the chemical
Figure 2. Light optical microscopy images of SPLA (A) and SPLA/BG (B) particles. No morphological differences between
polymeric and composite particles are visible.
Figure 3. SEM image of SPLA (A; B, a detail of the rougher surface) and SPLA/BG particles (C). There are no clear
morphological differences between the two types of particles.
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analysis of Si, Ca, and P in immersion solution for the
analyzed time points.
As can be seen in Figure 4(A), BG 45S5 was success-
fully incorporated into SPLA/BG particles, as seen by
the cumulative Si release for the immersion times. As
for SPLA particles, no Si release was observed, as
would be expected. Together with the Si elution from
SPLA/BG particles, variations in Ca and P concentra-
tions were also observed. Regarding calcium, its con-
centration in solution decreased, indicating that this
ion was being deposited at the surface of the particles
[Fig. 4(B)]. Interestingly, this behavior was only ob-
served with the composite particles. Concomitantly,
there was also a decrease in phosphate concentration
on the solution [Fig. 4(C)], as described for calcium.
For all the immersion periods, SPLA particles did not
produce an uptake of these ions, suggesting absence of
bioactive behavior of these microparticles.
Morphological analysis of immersed SPLA/BG
particles
SEM micrographs of the surface of SPLA and
SPLA/BG particles immersed for 21 days are shown
in Figure 5. Evident are the differences between the
surface of SPLA (A) and SPLA/BG (B,C) particles,
where SPLA does not evidence Ca-P precipitation op-
positely to SPLA/BG particles, which have their sur-
face fully covered by Ca-P nuclei. The morphological
analysis of the surface of SPLA/BG particles, com-
bined with the EDS analysis (Fig. 6), conﬁrms the
presence of a layer of calcium phosphate [Fig. 5(B)].
Higher-magniﬁcation Figure 5(C) shows that this
layer displays the typical morphology of a bone-like
calcium phosphate.
EDS analysis (Fig. 6) was performed to establish the
ionic composition of the layer, which is conﬁrmed to
be a calcium phosphate by the respective peaks. The
presence of chloride is the result of the synthesis in
which methylene chloride is used. There is some re-
sidual chloride after washing of the particles.
The immersed particles were also evaluated by FTIR-
ATR (Fig. 7) and although there is some overlap between
the spectra of the polymer and the typical spectra of BG
45S5, it is possible to observe the typical P-O band of
reacted BG 45S5 at 1080 cm1 at 21 days. Other charac-
teristic BG 45S5 bands are not visible because of the
overlap with some of the polymer bands.
Finally, the XRD pattern (Fig. 8) of the particles was
obtained, and upon comparison with the reference
hydroxylapatite (HA) spectra, the appearance of the
characteristic peaks of HA on the composite particles
is visible after day 14 of immersion.
In Figure 8, the XRD patterns of the composite parti-
cles are shown after 0, 14, and 21 days of immersion in
TE. The arrows indicate the main peaks characteristic of
HA. It is seen that at 21 days the main HA peaks as well
as some less evident peaks (indicated by the dashed
arrows) are present in the composite microparticles. This
indicates that at the surface of the composite particles a
Ca-P layer similar to HA was formed.
Short-term cytotoxicity
The results for the short-term cytotoxicity evalua-
tion are present in Figures 9 (MTT) and 10 (total
protein quantiﬁcation).
Figure 4. Si release (A) and Ca (B) and P (C) uptake proﬁles during 21 days of immersion in TE (control). Measurements
were made on control solutions (Ctrl) and solutions in which either SPLA or SPLA/BG particles were previously immersed.
446 SILVA ET AL.
As for total protein quantiﬁcation, the results are
presented as percentages of the control, meaning that
the values obtained are in comparison with the 100%
proliferation attributed to the control.
As can be seen, both materials—SPLA and SPLA/
BG—present values close to the one from the control,
for both materials above 89%, which is a good indica-
tion of their noncytotoxic behavior.
This result is well correlated with the MTT results,
in which both materials present again viability per-
centages above 86% (Fig. 10). Some difference is ob-
served between the results for the polymer and com-
Figure 5. SEM images with increasing magniﬁcation of the surface of SPLA (A) and SPLA/BG microparticles immersed for
21 days. The surface of SPLA particles does not evidence any Ca-P deposition (A), whereas for SPLA/BG particles, the surface
is fully covered with a Ca-P layer (B) having the globular structure (C).
Figure 6. EDS of SPLA/BG particles immersed for 21 days.
Calcium and phosphate peaks conﬁrm the presence of a
calcium-phosphate layer at the surface.
Figure 7. FTIR spectra for SPLA/BG particles at 0, 14, and
21 days of immersion, (A) full spectra and (B) spectra from
1300–500 cm1. The arrow indicates the characteristic P-O
band that appears when a Ca-P layer is formed on the
surface of the material.
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posite materials and the T test was performed to
assess whether signiﬁcant differences existed between
the tested materials for each of the tests, but there
were no signiﬁcant differences between the two ma-
terials (p  0.05).
CONCLUSIONS
The synthesis of both polymeric and composite
starch/BG particles was successfully achieved, as par-
ticles with spherical morphology and a well-deﬁned
size range were produced. Immersion in a simulated
body ﬂuid for periods up to 21 days showed that BG
45S5 was incorporated into the polymer particles (as
seen by Si release from composite particles) and that
its presence rendered the particles bioactive. The bio-
active nature of the composite starch–BG 45S5 parti-
cles was identiﬁed through morphological, chemical,
and structural analyses. These experiments revealed
the presence of a calcium phosphate layer at the sur-
face of SPLA/BG particles.
As for their short-term cytotoxicity, these materials
have shown a noncytotoxic behavior when evaluated
in indirect contact tests with a cell line. Both per-
formed tests—MTT and total protein quantiﬁcation—
have shown to yield identical results, and the tested
materials have shown a viability proﬁle close to the
one from control cells.
The aim is to use these particles as systems for the
release of bone growth factors, such as bone morpho-
genetic proteins (BMPs). By virtue of a combination of
bioactive behavior herein assessed and by the ability
to encapsulate bioactive agents,16 these microparticles
have a great potential for a controlled growth factor
release related to bone applications.
Other properties that will also be studied are their
bone bonding ability in vivo and their use as injectable
bone ﬁllers. Future studies will include the loading of
the particles with BMPs to study the incorporation
and release of BMP into the particles, in vitro cell
culture studies, and in vivo studies in small animals.
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